387 related articles for article (PubMed ID: 27892653)
1. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
[TBL] [Abstract][Full Text] [Related]
2. The proportion of circulating CD45RO
Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
[TBL] [Abstract][Full Text] [Related]
3. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
4. Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.
Domaica CI; Fuertes MB; Uriarte I; Girart MV; Sardañons J; Comas DI; Di Giovanni D; Gaillard MI; Bezrodnik L; Zwirner NW
PLoS One; 2012; 7(12):e51677. PubMed ID: 23240056
[TBL] [Abstract][Full Text] [Related]
5. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
6. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals.
Tarazona R; Casado JG; Delarosa O; Torre-Cisneros J; Villanueva JL; Sanchez B; Galiani MD; Gonzalez R; Solana R; Peña J
J Clin Immunol; 2002 May; 22(3):176-83. PubMed ID: 12078859
[TBL] [Abstract][Full Text] [Related]
7. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
[TBL] [Abstract][Full Text] [Related]
8. Low-frequency, exhausted immune status of CD56
Pan Z; Zhao R; Shen Y; Liu K; Xue W; Liang C; Peng M; Hu P; Chen M; Xu H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108369. PubMed ID: 34844872
[TBL] [Abstract][Full Text] [Related]
9. Loss of CCR7 expression on CD56(bright) NK cells is associated with a CD56(dim)CD16⁺ NK cell-like phenotype and correlates with HIV viral load.
Hong HS; Ahmad F; Eberhard JM; Bhatnagar N; Bollmann BA; Keudel P; Ballmaier M; Zielinska-Skowronek M; Schmidt RE; Meyer-Olson D
PLoS One; 2012; 7(9):e44820. PubMed ID: 23028633
[TBL] [Abstract][Full Text] [Related]
10. Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.
Chalan P; Bijzet J; Kroesen BJ; Boots AM; Brouwer E
J Rheumatol; 2016 Jun; 43(6):1008-16. PubMed ID: 27036380
[TBL] [Abstract][Full Text] [Related]
11. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
Yu J; Mao HC; Wei M; Hughes T; Zhang J; Park IK; Liu S; McClory S; Marcucci G; Trotta R; Caligiuri MA
Blood; 2010 Jan; 115(2):274-81. PubMed ID: 19897577
[TBL] [Abstract][Full Text] [Related]
12. NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.
Sottile R; Tannazi M; Johansson MH; Cristiani CM; Calabró L; Ventura V; Cutaia O; Chiarucci C; Covre A; Garofalo C; Pontén V; Tallerico R; Frumento P; Micke P; Maio M; Kärre K; Carbone E
Int J Cancer; 2019 Oct; 145(8):2238-2248. PubMed ID: 31018250
[TBL] [Abstract][Full Text] [Related]
13. Multicolor flow cytometric analysis of TLR2 and TLR9 expression and function in NK cells from patients with ANCA-associated vasculitis.
Scrivo R; Peruzzi G; Gattamelata A; Gross CC; Carletti R; Di Gioia C; Brandt J; Priori R; Morrone S; Santoni A; Valesini G
Cytometry B Clin Cytom; 2018 May; 94(3):412-422. PubMed ID: 28834234
[TBL] [Abstract][Full Text] [Related]
14. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients.
Vuletić A; Jurišić V; Jovanić I; Milovanović Z; Nikolić S; Konjević G
J Surg Res; 2013 Aug; 183(2):860-8. PubMed ID: 23522458
[TBL] [Abstract][Full Text] [Related]
15. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.
Lima M; Almeida J; Montero AG; Teixeira Mdos A; Queirós ML; Santos AH; Balanzategui A; Estevinho A; Algueró Mdel C; Barcena P; Fonseca S; Amorim ML; Cabeda JM; Pinho L; Gonzalez M; San Miguel J; Justiça B; Orfão A
Am J Pathol; 2004 Oct; 165(4):1117-27. PubMed ID: 15466379
[TBL] [Abstract][Full Text] [Related]
16. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells.
Wendt K; Wilk E; Buyny S; Buer J; Schmidt RE; Jacobs R
J Leukoc Biol; 2006 Dec; 80(6):1529-41. PubMed ID: 16966385
[TBL] [Abstract][Full Text] [Related]
17. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals.
Korbel DS; Norman PJ; Newman KC; Horowitz A; Gendzekhadze K; Parham P; Riley EM
J Immunol; 2009 May; 182(10):6426-34. PubMed ID: 19414796
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell lytic activity and CD56(dim) and CD56(bright) cell distributions during and after intensive training.
Suzui M; Kawai T; Kimura H; Takeda K; Yagita H; Okumura K; Shek PN; Shephard RJ
J Appl Physiol (1985); 2004 Jun; 96(6):2167-73. PubMed ID: 14752119
[TBL] [Abstract][Full Text] [Related]
19. [Human peripheral blood CD56+ natural killer cell subsets and their phenotypic and biological properties].
Wu CY; Liu J; Yang BY; Roedere M
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):169-72. PubMed ID: 16875598
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
